Salix's Xifaxan Draws Ambivalent Recommendation From Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Salix's Xifaxan for hepatic encephalopathy passed advisory committee review, but members expressed unease about lingering safety concerns and called for additional studies.